Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis
2012
In an unadjusted intention-to-treat analysis, cinacalcet did not significantly reduce the risk of death or major cardiovascular events in patients with moderate-to-severe secondary hyperparathyroidism who were undergoing dialysis. (Funded by Amgen; EVOLVE ClinicalTrials.gov number, NCT00345839.).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
40
References
686
Citations
NaN
KQI